AU2001284880A1 - Preparation of risperidone - Google Patents

Preparation of risperidone

Info

Publication number
AU2001284880A1
AU2001284880A1 AU2001284880A AU8488001A AU2001284880A1 AU 2001284880 A1 AU2001284880 A1 AU 2001284880A1 AU 2001284880 A AU2001284880 A AU 2001284880A AU 8488001 A AU8488001 A AU 8488001A AU 2001284880 A1 AU2001284880 A1 AU 2001284880A1
Authority
AU
Australia
Prior art keywords
risperidone
risperidone form
isopropanol
butanol
solvent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001284880A
Other languages
English (en)
Inventor
Judith Aronhime
Dov Diller
Ben-Zion Dolitzky
Barnaba Krochmal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceutical Industries Ltd
Original Assignee
Teva Pharmaceutical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26919535&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2001284880(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva Pharmaceutical Industries Ltd filed Critical Teva Pharmaceutical Industries Ltd
Publication of AU2001284880A1 publication Critical patent/AU2001284880A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU2001284880A 2000-08-14 2001-08-14 Preparation of risperidone Abandoned AU2001284880A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US22536100P 2000-08-14 2000-08-14
US60/225,361 2000-08-14
US24326300P 2000-10-25 2000-10-25
US60/243,263 2000-10-25
PCT/US2001/025387 WO2002014286A1 (en) 2000-08-14 2001-08-14 Preparation of risperidone

Publications (1)

Publication Number Publication Date
AU2001284880A1 true AU2001284880A1 (en) 2002-02-25

Family

ID=26919535

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001284880A Abandoned AU2001284880A1 (en) 2000-08-14 2001-08-14 Preparation of risperidone

Country Status (20)

Country Link
US (2) US6750341B2 (enExample)
EP (2) EP1317434A4 (enExample)
JP (3) JP3751942B2 (enExample)
KR (2) KR100818875B1 (enExample)
AT (1) ATE401313T1 (enExample)
AU (1) AU2001284880A1 (enExample)
CA (1) CA2419314C (enExample)
CZ (1) CZ2003668A3 (enExample)
DE (1) DE60134899D1 (enExample)
ES (1) ES2310410T3 (enExample)
HR (1) HRP20030154B1 (enExample)
HU (1) HUP0302874A2 (enExample)
IL (2) IL154417A0 (enExample)
IS (1) IS6713A (enExample)
MX (1) MXPA03001337A (enExample)
NZ (1) NZ524554A (enExample)
PL (1) PL365608A1 (enExample)
PT (1) PT1783118E (enExample)
SK (1) SK2982003A3 (enExample)
WO (1) WO2002014286A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7666445B2 (en) * 2000-10-20 2010-02-23 The Trustees Of The University Of Pennsylvania Polymer-based surgically implantable haloperidol delivery systems and methods for their production and use
AU2003256006A1 (en) * 2002-08-30 2004-03-19 Sunil Sadanand Nadkarni Improved process for preparation of risperidone
KR20040034996A (ko) * 2002-10-18 2004-04-29 한미약품 주식회사 리스페리돈의 개선된 제조방법
CN100390146C (zh) 2002-11-13 2008-05-28 斯索恩有限公司 制备利培酮的方法和用于该方法的中间体
US20040180935A1 (en) * 2003-02-28 2004-09-16 Dr. Reddy's Laboratories Limited Dr. Reddy's Laboratories Inc. Crystalline form Z of rabeprazole sodium and process for preparation thereof
AU2003245028A1 (en) * 2003-04-16 2004-11-04 Hetero Drugs Limited A novel crystalline form of risperidone
US7714128B2 (en) 2003-10-16 2010-05-11 Symed Labs Limited Crystalline form of linezolid
US8221778B2 (en) 2005-01-12 2012-07-17 The Trustees Of The University Of Pennsylvania Drug-containing implants and methods of use thereof
US8329203B2 (en) * 2004-01-12 2012-12-11 The Trustees Of The University Of Pennsylvania Drug-containing implants and methods of use thereof
AU2005206143B2 (en) * 2004-01-12 2010-12-16 The Trustees Of The University Of Pennsylvania Long-term delivery formulations and methods of use thereof
PL1737850T3 (pl) * 2004-04-19 2008-02-29 Symed Labs Ltd Nowy sposób wytwarzania linezolidu i związków pokrewnych
HUP0401379A3 (en) * 2004-07-08 2006-04-28 Richter Gedeon Vegyeszet Process for the preparation of risperidon
US20080262445A1 (en) * 2004-09-08 2008-10-23 Dermatrends, Inc. Transdermal Delivery of Hydrophobic Bioactive Agents
HUP0402163A2 (en) * 2004-10-25 2006-05-29 Richter Gedeon Vegyeszet Process for the preparation of risperidone
CN101198869A (zh) * 2005-04-27 2008-06-11 株式会社Umn制药 胰腺炎的预防及治疗剂
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
WO2007093870A2 (en) * 2006-02-15 2007-08-23 Orchid Chemicals & Pharmaceuticals Limited A process for the preparation of risperidone
US7820816B2 (en) * 2006-08-23 2010-10-26 Teva Pharmaceutical Industries Ltd. Process for the synthesis of CMHTP and intermediates thereof
CA2687979C (en) 2007-05-25 2017-07-04 Tolmar Therapeutics, Inc. Sustained delivery formulations of risperidone compounds
CA2750028C (en) 2009-01-20 2019-05-07 Guochuan Emil Tsai Sorbic and benzoic acid and derivatives thereof enhance the activity of a neuropharmaceutical
CN102786521B (zh) * 2011-05-18 2016-01-13 中国医学科学院药物研究所 利培酮晶iii型物质及制备方法与在药品和保健品中应用
CN105367570B (zh) * 2015-12-08 2017-10-10 天津市亨必达化学合成物有限公司 一种利培酮晶i型物质的制备方法
CN109563024B (zh) 2016-06-13 2023-06-06 心悦生医股份有限公司 苯甲酸锂的共晶及其用途
CN109563018A (zh) 2016-06-13 2019-04-02 心悦生医股份有限公司 苯甲酸钠的共晶及其用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4804663A (en) * 1985-03-27 1989-02-14 Janssen Pharmaceutica N.V. 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
US5158952A (en) * 1988-11-07 1992-10-27 Janssen Pharmaceutica N.V. 3-[2-[4-(6-fluoro-1,2-benzisoxozol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9 tetrahydro-9-hydroxy-2-methyl-4H-pyrido [1,2-a]pyrimidin-4-one, compositions and method of use
ES2050069B1 (es) 1992-07-10 1994-12-16 Vita Invest Sa Procedimiento para la obtencion de 3-(2-(4-(6-fluoro-1,2-benzisoxazol-3-il)piperidino)etil)-2-metil-6,7,8,9-tetrahidro-4h-pirido(1,2-a) pirimidin-4-ona.
ES2074966B1 (es) 1994-02-11 1996-06-16 Vita Invest Sa Procedimiento para la obtencion de 3-(2-(4-(6-fluoro-benzo(d)isoxazol-3-il)piperidin-1-il)-etil)-2-metil-6,7,8,9-tetrahidro-4h-pirido-(1,2-a)pirimidin-4-ona.
EP0877613A2 (en) * 1996-01-26 1998-11-18 PHARMACIA & UPJOHN COMPANY Use of a combination of delavirdine and one or more protease inhibitors in hiv-1 infected patients
TW487572B (en) * 1996-05-20 2002-05-21 Janssen Pharmaceutica Nv Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters
IT1294931B1 (it) * 1997-09-22 1999-04-23 Sigma Tau Ind Farmaceuti Derivati della 2-amminotetralina procedimento per la loro preparazione e composizioni farmaceutiche che li contengono, attive nella
EP1280804B1 (en) 2000-05-05 2004-04-14 RPG Life Sciences Limited A process for the preparation of anti-psychotic 3- 2- 4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4h-pyrido 1,2,-a]pyrimidin-4-one
US20020115672A1 (en) * 2000-08-08 2002-08-22 Barnaba Krochmal Preparation of risperidone
US20020193386A1 (en) 2002-03-28 2002-12-19 Inigo Pfeiffer Polymorphic form of 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-alpha]pyrimidin-4-one and formulations thereof

Also Published As

Publication number Publication date
WO2002014286A9 (en) 2003-03-27
ES2310410T3 (es) 2009-01-01
EP1317434A1 (en) 2003-06-11
JP3751942B2 (ja) 2006-03-08
SK2982003A3 (en) 2004-10-05
DE60134899D1 (de) 2008-08-28
ATE401313T1 (de) 2008-08-15
NZ524554A (en) 2005-07-29
KR20030022389A (ko) 2003-03-15
KR20080028513A (ko) 2008-03-31
CA2419314C (en) 2006-07-11
JP2008056699A (ja) 2008-03-13
MXPA03001337A (es) 2005-06-30
WO2002014286A1 (en) 2002-02-21
JP2006028192A (ja) 2006-02-02
CA2419314A1 (en) 2002-02-21
IL154417A0 (en) 2003-09-17
US7256195B2 (en) 2007-08-14
EP1982980A1 (en) 2008-10-22
HRP20030154B1 (en) 2009-03-31
HRP20030154A2 (en) 2005-04-30
HUP0302874A2 (hu) 2003-12-29
CZ2003668A3 (en) 2004-04-14
IS6713A (is) 2003-02-11
JP2004506622A (ja) 2004-03-04
KR100818875B1 (ko) 2008-04-01
US20040229905A1 (en) 2004-11-18
IL154417A (en) 2008-11-03
US6750341B2 (en) 2004-06-15
PT1783118E (pt) 2008-08-19
EP1317434A4 (en) 2005-06-22
PL365608A1 (en) 2005-01-10
US20020115673A1 (en) 2002-08-22

Similar Documents

Publication Publication Date Title
US6750341B2 (en) Preparation of risperidone
US3700673A (en) 3-4-dihydrobenzo(b) (1,7)naphthyridin-1(2h)-ones
EP0252503B1 (en) Aminoimidazoquinoline derivatives
US4020072A (en) 5-Aminomethyl-1H-pyrazolo[3,4-b]pyridines
AU680320B2 (en) Morpholine derivatives as dopamine receptor subtype ligands
SU999972A3 (ru) Способ получени производных пиридо-(1,2-а) пиримидина или их фармацевтически приемлемых солей,или их оптически активных изомеров
US20020115672A1 (en) Preparation of risperidone
JPH0347179A (ja) Ｎ―ヘテロアリール―４―キノリンアミンおよびその製造法
CN114507230B (zh) 一种双环吡啶酮类衍生物、其合成方法及其用途
EP1783118B1 (en) Preparation of risperidone
CA2535728C (en) Preparation of risperidone
US4048184A (en) 6-Phenyl-2H-pyrazolo[3,4-b]pyridines
US3960847A (en) 9-Substituted-4-oxopyrido(1,2-α)pyrimidine-3-carboxylic acids and derivatives thereof
US4623725A (en) [1,2,4]Triazolo[4,3-a]quinoxaline-4-amine derivatives
ZA200301200B (en) Preparation of risperidone.
CA2549398A1 (en) Preparation of risperidone
US20060004199A1 (en) Process for the preparation of pure 3-[2-[4-(6-fluoro-1, 2-benzisoxazol-3-yl)-1-piperidinyl]-ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido [1,2-a] pyrimidin-4-one
EP0277625A2 (en) Tetrahydropyrido[3',4':4,5]pyrrolo[2,3-c]quinolines, intermediates and a process for the preparation thereof and their use as hypotensive agents
WO2012007952A1 (en) Novel polymorph of irinotecan hydrochloride
JPH04103572A (ja) ４―フェニル―２―（１―ピペラジニル）ピリジン誘導体

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application